RhumbLine Advisers
CDAK

RhumbLine Advisers’s Codiak BioSciences, Inc. Common Stock CDAK Stock Holding History

RhumbLine Advisers’s Portfolio CDAK Stock Details CDAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,218
Closed -$83K – 3308
2022
Q1 		$83K Buy
+13,218
New +$83K ﹤0.01% 2921

Other funds holding CDAK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

RhumbLine Advisers's CDAK Position: Q2 2022 in Review

RhumbLine Advisers sold out of Codiak BioSciences, Inc. Common Stock (CDAK) in Q2 2022, closing a stake of 13,218 shares — an estimated $83K sold.

RhumbLine Advisers first reported a position in CDAK in Q1 2022 and held it in 1 quarter. The position peaked at $83K in Q1 2022. 49 funds tracked by Wall St. Rank hold CDAK as of Q2 2022.

  • RhumbLine Advisers reported no remaining Codiak BioSciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • RhumbLine Advisers sold 13,218 Codiak BioSciences, Inc. Common Stock shares in Q2 2022, an estimated $83K.
  • RhumbLine Advisers first reported a position in Codiak BioSciences, Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • RhumbLine Advisers's Codiak BioSciences, Inc. Common Stock position peaked at $83K in Q1 2022.
  • 49 funds tracked by Wall St. Rank held Codiak BioSciences, Inc. Common Stock as of Q2 2022.

Based on RhumbLine Advisers's 13F filing for Q2 2022, filed 11 Aug 2022.